Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial

Isabelle Krämer, Stephan Stilgenbauer, Sascha Dietrich, Sebastian Böttcher, Matthias Zeis, Michael Stadler, Jörg Bittenbring, Lutz Uharek, Christof Scheid, Ute Hegenbart, Anthony Ho, Michael Hallek, Michael Kneba, Norbert Schmitz, Hartmut Döhner, Peter Dreger

Blood (2017) 130 (12): 1477–1480.

https://doi.org/10.1182/blood-2017-04-775841

Published: 2017

Includes: Supplemental data

Journal Articles

Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial

Isabelle Krämer, Stephan Stilgenbauer, Sascha Dietrich, Sebastian Böttcher, Matthias Ritgen, Donald Bunjes, Matthias Zeis, Michael Stadler, MD, Joerg Thomas Bittenbring, MD, Ute Hegenbart, Michael Hallek, Michael Kneba, Norbert Schmitz, MD, PhD, Hartmut Döhner, MD, Peter Dreger, MD

Blood (2016) 128 (22): 682.

https://doi.org/10.1182/blood.V128.22.682.682

Published: 2016

Journal Articles

Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma

Maximilian Merz, MD, Hans-Juergen Salwender, MD, Mathias Haenel, MD, Uta Bertsch, MD, Christina Kunz, Thomas Hielscher, Igor W. Blau, MD, Christof Scheid, MDPhD, Elias Karl Mai, MD, Dirk Hose, MD, Bärbel Schurich, Markus Munder, MD, Peter Brossart, MD, Christian Gerecke, MD, Hans Walter Lindemann, MD, Matthias Zeis, MD, Katja C. Weisel, Jan Duerig, MD, Hartmut Goldschmidt, MD

Blood (2015) 126 (23): 4233.

https://doi.org/10.1182/blood.V126.23.4233.4233

Published: 2015

Journal Articles

Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG

Christof Scheid, MDPhD, Thomas Hielscher, Uta Bertsch, MD, Christina Kunz, PhD, Hans Salwender, MD, Mathias Haenel, Maximilian Merz, Elias Karl Mai, MD, Dirk Hose, MD PhD, Baerbel Schurich, PhD, Markus Munder, MD, Ingo Schmidt-Wolf, MD, Christian Gerecke, MD, Walter Lindemann, MD, Matthias Zeis, MD, Katja Weisel, MD, Jan Duerig, MD, Anna Jauch, PhD, Hartmut Goldschmidt, MD

Blood (2014) 124 (21): 4777.

https://doi.org/10.1182/blood.V124.21.4777.4777

Published: 2014

Journal Articles

Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial

Maximilian Merz, MD, Hans Salwender, MD, Mathias Hänel, MD, Uta Bertsch, MD, Christina Kunz, PhD, Thomas Hielscher, Igor W. Blau, MD, Christof Scheid, MDPhD, Elias Karl Mai, MD, Dirk Hose, MD, Baerbel Schurich, PhD, Markus Munder, MD, Ingo GH Schmidt-Wolf, MD, Christian Gerecke, MD, Hans Walter Lindemann, MD, Matthias Zeis, MD, Katja Weisel, MD, Jan Duerig, MD, Hartmut Goldschmidt, MD

Blood (2014) 124 (21): 3475.

https://doi.org/10.1182/blood.V124.21.3475.3475

Published: 2014

Journal Articles

Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial

Annika Scheffold, MSc, Billy Michael Chelliah Jebaraj, PhD, Eugen Tausch, MD, Sebastian Boettcher, MD, Matthias Ritgen, Donald Bunjes, MD, Matthias Zeis, MD, Michael Stadler, MD, Lutz Uharek, MD, Christof Scheid, MDPhD, Ute Hegenbart, MD, Michael Hallek, MD, Michael Kneba, MD PhD, Norbert Schmitz, MD PhD, Hartmut Doehner, MD, Peter Dreger, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 1951.

https://doi.org/10.1182/blood.V124.21.1951.1951

Published: 2014

Journal Articles

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

Blood (2013) 122 (21): 3369.

https://doi.org/10.1182/blood.V122.21.3369.3369

Published: 2013

Journal Articles

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

Blood (2013) 122 (21): 1897.

https://doi.org/10.1182/blood.V122.21.1897.1897

Published: 2013

Journal Articles

TP53 , SF3B1 , and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

Blood (2013) 121 (16): 3284–3288.

https://doi.org/10.1182/blood-2012-11-469627

Published: 2013

Includes: Supplemental data

Journal Articles

Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial

Thorsten Zenz, MD, Peter Dreger, MD, PhD, Sascha Dietrich, MD, Sebastian Böttcher, MD, Matthias Ritgen, MD, Dirk Winkler, MD, Andreas Bühler, MD, Donald Bunjes, MD, Dietrich Beelen, MD, Sandra Cohen, MD, FRCPC, Ute Hegenbart, MD, Matthias Zeis, MD, Michael Hallek, M.D., Michael Kneba, MD, PhD, Norbert Schmitz, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, M.D.

Blood (2010) 116 (21): 2357.

https://doi.org/10.1182/blood.V116.21.2357.2357

Published: 2010

Journal Articles

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Blood (2010) 116 (14): 2438–2447.

https://doi.org/10.1182/blood-2010-03-275420

Published: 2010

Includes: Supplemental data

Journal Articles

Prior Treatment with Alemtuzumab Interferes with T-Cell Engraftment After Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia.

Johannes Schetelig, Christian Thiede, Alexander Kiani, Uwe Platzbecker, Uta Oelschlaegel, Matthias Haenel, Gaby Geissler, Rainer Schwerdtfeger, MD, Karin Kolbe, MD, Martin Kaufmann, Matthias Zeis, MD, Kerstin Schaefer-Eckart, MD, Wolfgang Siegert, MD, PhD, Gerhard Ehninger

Blood (2009) 114 (22): 3351.

https://doi.org/10.1182/blood.V114.22.3351.3351

Published: 2009

Journal Articles

Humoral Immune Responses against the Immature Laminin Receptor Show Prognostic Significance in Patients with Multiple Myeloma.

Matthias Zeis, Sandra Siegel, Birte Friedrichs, Norbert Schmitz, MD, PhD

Blood (2008) 112 (11): 1534.

https://doi.org/10.1182/blood.V112.11.1534.1534

Published: 2008

Journal Articles

Humoral Immune Responses Against the Oncofetal-Antigen/Immature Laminin Receptor (OFA/iLR) in Patients with Chronic Lymphocytic Leukemia.

Birte Friedrichs, MD, Sandra Siegel, Norbert Schmitz, MD, Matthias Zeis, MD

Blood (2006) 108 (11): 2820.

https://doi.org/10.1182/blood.V108.11.2820.2820

Published: 2006

Journal Articles

Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies

Sandra Siegel, Andreas Wagner, Dieter Kabelitz, Matthias Marget, Joseph Coggin, Jr, Adel Barsoum, James Rohrer, Norbert Schmitz, Matthias Zeis

Blood (2003) 102 (13): 4416–4423.

https://doi.org/10.1182/blood-2003-01-0198

Published: 2003

Journal Articles

Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells

Christof Lehmann, Matthias Zeis, Norbert Schmitz, Lutz Uharek

Blood (2000) 96 (2): 594–600.

https://doi.org/10.1182/blood.V96.2.594

Published: 2000

Journal Articles

Allogeneic Peripheral Blood Progenitor Cell Transplantation in a Murine Model: Evidence for an Improved Graft-Versus-Leukemia Effect

Bertram Glass, Lutz Uharek, Matthias Zeis, Peter Dreger, Helmut Löffler, Jörg Steinmann, Norbert Schmitz

Blood (1997) 90 (4): 1694–1700.

https://doi.org/10.1182/blood.V90.4.1694

Published: 1997

NARROW

Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial

Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial

Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma

Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG

Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial

Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

TP53 , SF3B1 , and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Prior Treatment with Alemtuzumab Interferes with T-Cell Engraftment After Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia.

Humoral Immune Responses against the Immature Laminin Receptor Show Prognostic Significance in Patients with Multiple Myeloma.

Humoral Immune Responses Against the Oncofetal-Antigen/Immature Laminin Receptor (OFA/iLR) in Patients with Chronic Lymphocytic Leukemia.

Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies

Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells

Allogeneic Peripheral Blood Progenitor Cell Transplantation in a Murine Model: Evidence for an Improved Graft-Versus-Leukemia Effect

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only